Showing results (261-270 of 319) with videos related to
Sort By:
Pageof 32
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 7, 2017
Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicityRanda Tao, Chiaojung Jillian Tsai, Garrett Jensen, et al.Journal for Immunotherapy of Cancer|June 7, 2023
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancerRonan J Kelly, Katherine Bever, Joseph Chao, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2017
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline UpdatePaul J Hesketh, Mark G Kris, Ethan Basch, et al.The Annals of Thoracic Surgery|September 27, 2013
Dual intervention to improve pathologic staging of resectable lung cancerRaymond U Osarogiagbon, Robert A Ramirez, Christopher G Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2018
Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort StudyJessica P Hwang, Anna S Lok, Michael J Fisch, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2026
NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal CanalVan K Morris, Kristen K Ciombor, Lianchun Xiao, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2008
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastasesDan G Blazer, Yoji Kishi, Dipen M Maru, et al.Oncotarget|June 4, 2021
CEA as a blood-based biomarker in anal cancerRobert Hester, Shailesh Advani, Asif Rashid, et al.The New England Journal of Medicine|May 30, 2025
Encorafenib, Cetuximab, and mFOLFOX6 in <i>BRAF</i>-Mutated Colorectal CancerElena Elez, Takayuki Yoshino, Lin Shen, et al.Ochsner Journal|December 13, 2017
Prognostic Factors in Typical and Atypical Pulmonary CarcinoidsRobert A Ramirez, David T Beyer, Anne E Diebold, et al.Pageof 32